The case for statin therapy in chronic heart failure

Clinical Research in Cardiology

Volumn 97, Issue 3, 2008, Pages 139-146

  Van Der Harst, Pim ^a   Böhm, Michael ^b   Van Gilst, Wiek H ^a   Van Veldhuisen, Dirk J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Cholesterol; Heart failure; Statins

Indexed keywords

AMLODIPINE; ATORVASTATIN; BISOPROLOL; CAPTOPRIL; CERIVASTATIN; CHOLESTEROL; ENDOTOXIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOSARTAN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UBIQUINONE; VALSARTAN;

CARDIOVASCULAR PARAMETERS; CHOLESTEROL DIET; CLINICAL TRIAL; DEFIBRILLATOR; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; HEART FAILURE; HUMAN; MORTALITY; NONHUMAN; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; REVIEW;

CHRONIC DISEASE; CLINICAL PROTOCOLS; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 44049092504     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-007-0610-0     Document Type: Review

References (47)

1. Afilalo J, Majdan AA, Eisenberg MJ (2007) Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomized controlled trials. Heart 93:914-921
2. Anker SD, Clark AL, Winkler R, Zugck C, Cicoira M, Ponikowski P, Davos CH, Banasiak W, Zardini P, Haass M, Senges J, Coats AJ, Poole-Wilson PA, Pitt B (2006) Statin use and survival in patients with chronic heart failure-results from two observational studies with 5200 patients. Int J Cardiol 112:234-242
3. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G (2001) Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104:982-985
4. Bleske BE, Nicklas JM, Bard RL, Brook RD, Gurbel PA, Bliden KP, Rajagopalan S, Pitt B (2006) Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 47:338-341
5. Bohm M, Hjalmarson A, Kjekshus J, Laufs U, McMurray J, Van Veldhuisen DJ (2005) Heart failure and statins-why do we need a clinical trial? Z Kardiol 94:223-230
6. Brouilette SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd J, Packard CJ, Samani NJ (2007) Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 369:107-114
7. De Pinieux G (1996) Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 42:333-337
8. Emberson JR, Ng LL, Armitage J, Bowman L, Parish S, Collins R (2007) N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol 49:311-319
9. Foody JM, Shah R, Galusha D, Masoudi FA, Havranek EP, Krumholz HM (2006) Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113:1086-1092
10. Genser B, Marz W (2006) Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis. Clin Res Cardiol 95:393-404
11. Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH (2006) Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 296:2105-2111
12. Groenewegen HC, van der Harst P, Roks AJ, Buikema H, Zijlstra F, van Gilst WH, de Smet BJ (2007) Effects of angiotensin II and angiotensin II type 1 receptor blockade on neointimal formation after stent implantation. Int J Cardiol [Epub ahead of print]
13. Hong YJ, Jeong MH, Hyun DW, Hur SH, Kim KB, Kim W, Lim SY, Lee SH, Hong SN, Kang DG, Yun KH, Kim KH, Lee YS, Park HW, Kim JH, Ahn YK, Cho JG, Park JC, Kang JC (2005) Prognostic significance of simvastatin therapy in patients with ischemic heart failure who underwent percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 95:619-622
14. Hoppe UC (2007) Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? AT1-receptor antagonists? Clin Res Cardiol 96:196-198
15. Ito M, Adachi T, Pimentel DR, Ido Y, Colucci WS (2004) Statins Inhibit {beta}-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism. Circulation 110:412-418
16. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC (2004) Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 43:1439-1444
17. Kjekshus J, Dunselman P, Blideskog M, Eskilson C, Hjalmarson A, McMurray JV, Waagstein F, Wedel H, Wessman P, Wikstrand J (2005) A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 7:1059-1069
18. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Kang MH, Ahn TH, Choi IS, Shin EK (2004) Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110:3687-3692
19. Krum H, Ashton E, Reid C, Kalff V, Rogers J, Amarena J, Singh B, Tonkin A (2007) Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 13:1-7
20. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, Manes C, Fischer D, de Groot K, Fliser D, Fauler G, Marz W, Drexler H (2005) Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111:2356-2363
21. Laufs U, Wassmann S, Schackmann S, Heeschen C, Bohm M, Nickenig G (2004) Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol 93:103-108
22. Marz W, Siekmeier R, Muller HM, Wieland H, Gross W, Olbrich HG (2000) Effects of lovastatin and pravastatin on the survival of hamsters with inherited cardiomyopathy. J Cardiovasc Pharmacol Ther 5:275-279
23. May HT, Muhlestein JB, Carlquist JF, Horne BD, Bair TL, Campbell BA, Kfoury AG, Lyon JL, Kim H, Renlund DG (2006) Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure. Am J Cardiol 98:653-658
24. Mortensen SA (2003) Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of "Q-symbio"- a multinational trial. Biofactors 18:79-89
25. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJS, Anker SD (1999) Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353:1838-1842
26. Node K, Fujita M, Kitakaze M, Hori M, Liao JK (2003) Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108:839-843
27. Rauchhaus M, Coats AJS, Anker SD (2000) The endotoxin-lipoprotein hypothesis. Lancet 356:930-933
28. Ray JG, Gong Y, Sykora K, Tu JV (2005) Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 165:62-67
29. Reibis R, Dovifat C, Dissmann R, Ehrlich B, Schulz S, Stolze K, Wegscheider K, Voller H (2006) Implementation of evidence-based therapy in patients with systolic heart failure from 1998-2000. Clin Res Cardiol 95:154-161
30. Saka M, Obata K, Ichihara S, Cheng XW, Kimata H, Nishizawa T, Noda A, Izawa H, Nagata K, Murohara T, Yokota M (2006) Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol 47:770-779
31. Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P, Shui A, McCabe CH, Braunwald E (2006) Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 47:2326-2331
32. Smetanina IN, Vaulin NA, Masenko VP, Gratsianskii NA (2006) Short term simvastatin use in patients with systolic heart failure of ischemic origin did not preclude elevation of n-terminal pro-brain natriuretic peptide level. Kardiologiia 46:12-16
33. Smetanina IN, Vaulin NA, Masenko VP, Gratsianskii NA (2006) Short term simvastatin use in patients with heart failure of ischemic origin. Changes of blood lipids, markers of inflammation and left ventricular function. Kardiologiia 46:44-49
34. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV (2006) Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47:332-337
35. Strey CH, Young JM, Molyneux SL, George PM, Florkowski CM, Scott RS, Frampton CM (2005) Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. Atherosclerosis 179:201-206
36. Su SF, Hsiao CL, Chu CW, Lee BC, Lee TM (2000) Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. Am J Cardiol 86:514-518
37. Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R, Nicolosi GL, Porcu M, on behalf of the GISSI-HF investigators (2004) Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 6:635-641
38. Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Tsioufis C, Tentolouris C, Trikas A, Pitsavos C, Stefanadis C (2005) Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 91:27-31
39. Van der Harst P, Asselbergs FW, Buikema H, Voors AA, Van Veldhuisen DJ, van Gilst WH (2006) Effects of C-reactive protein and cholesterol on responsiveness in vitro of the internal thoracic artery to angiotensin II in patients having coronary artery bypass grafting. Am J Cardiol 98:751-753
40. Van der Harst P, Voors AA, van Gilst WH, Bohm M, Van Veldhuisen DJ (2006) Statins in the treatment of chronic heart failure: a systematic review. PLoS Med 3:e333
41. Van der Harst P, Voors AA, van Gilst WH, Bohm M, Van Veldhuisen DJ (2006) Statins in the treatment of chronic heart failure: biological and clinical considerations. Cardiovasc Res 71:443-454
42. Van der Harst P, Voors AA, Volbeda M, Buikema H, Van Veldhuisen DJ, van Gilst WH (2006) Usefulness of preoperative C-reactive protein and soluble intercellular adhesion molecule-1 level for predicting future cardiovascular events after coronary artery bypass grafting. Am J Cardiol 97:1697-1701
43. Van der Harst P, Wagenaar LJ, Buikema H, Voors AA, Plokker HW, Morshuis WJ, Six AJ, Boonstra PW, Nickenig G, Wassmann S, Van Veldhuisen DJ, van Gilst WH (2005) Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin ii in stable coronary artery disease. Am J Cardiol 96:1361-1364
44. Van der Harst P, van der Steege G, De Boer RA, Voors AA, Hall AS, Mulder MJ, van Gilst WH, Van Veldhuisen DJ, MERIT-HF Study Group (2007) Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. J Am Coll Cardiol 49:1459-1464
45. Van der Horst I, Voors AA, Van Veldhuisen DJ (2007) Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists? Clin Res Cardiol 96:193-195
46. Westenbrink BD, Lipsic E, van der Meer P, van der Harst P, Oeseburg H, Du Marchie Sarvaas GJ, Koster J, Voors AA, Van Veldhuisen DJ, van Gilst WH, Schoemaker RG (2007) Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 28:2018-2027
47. Wojnicz R, Wilczek K, Nowalany-Kozielska E, Szygula-Jurkiewicz B, Nowak J, Polonski L, Dyrbus K, Badzinski A, Mercik G, Zembala M, Wodniecki J, Rozek MM (2006) Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 97:899-904